Source comparison
MOTS-c Side Effects Long Term Research: Comparison Across Mitochondrial Peptides
| Peptide | Human Trial Duration (Max) | Common Short-Term Side Effects | Long-Term Animal Data | Immune Sensitisation Risk | Professional Assessment ||—|—|—|—|—|| MOTS-c | 12 weeks | Injection site reactions (18%), transient headache (rare), mild fatigue | 18
This comparison does not assign a generated winner or score.
- | Peptide | Human Trial Duration (Max) | Common Short-Term Side Effects | Long-Term Animal Data | Immune Sensitisation Risk | Professional Assessment ||—|—|—|—|—|| MOTS-c | 12 weeks | Injection site reactions (18%), transient headache (rare), mild fatigue | 18-month murine lifespan studies show no organ toxicity or tumour increase | Low. Endogenous peptide with minimal epitope formation | Best short-term safety profile among mitochondrial peptides; long-term human data still absent || Humanin | 8 weeks | Rare injection site reactions, no systemic AEs reported in Phase I | 12-month rodent studies show neuroprotective effects without adverse histology | Low. Naturally occurring peptide | Limited human data; mechanistic safety reassuring || SS-31 (Elamipretide) | 28 weeks (Phase II) | Injection site reactions (15%), transient chromatopsia (visual colour distortion) | No organ toxicity in 6-month primate studies | Low to moderate. Synthetic analog of natural cardiolipin-targeting peptide |